Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma

被引：0
|
作者：
Goyal, L. [1 ]
Baiev, I. [1 ]
Zhang, K. [2 ]
Dalgai, S. [3 ]
Shroff, R. T. [4 ]
Kelley, R. K. [2 ]
Uboha, N. [5 ]
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Oncol, Boston, MA 02114 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Gastrointestinal Oncol, San Francisco, CA 94143 USA
[3] Univ Arizona, Dept Med, Coll Med, Tucson, AZ USA
[4] Univ Arizona, Div Hematol & Oncol, Coll Med, Tucson, AZ USA
[5] Univ Wisconsin, Div Hematol & Oncol, Carbone Canc Ctr, Madison, WI USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [41] FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
    King, Gentry
    Javle, Milind
    CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
  • [42] Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas
    Cowell, John K.
    Qin, Haiyan
    Hu, Tianxiang
    Wu, Qing
    Bhole, Aaron
    Ren, Mingqiang
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (09) : 1822 - 1829
  • [43] FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC
    Nogova, L.
    Malchers, F.
    Hillmer, A.
    Merkelbach-Bruse, S.
    Pinto, A.
    Woempner, C.
    Riedel, R.
    Scheffler, M.
    Michels, S.
    De Porre, P.
    Santiago-Walker, A.
    Fischer, R. N.
    Abdulla, D. S.
    Thomas, R.
    Buettner, R.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] FGFR inhibition in cholangiocarcinoma
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (05): : 425 - 426
  • [45] Erdafitinib Improves Overall Survival vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
    George, Daniel
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 366 - 366
  • [46] FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC
    Nogova, L.
    Malchers, F.
    Hillmer, A.
    Merkelbach-Bruse, S.
    Pinto, A.
    Woempner, C.
    Scheel, A.
    Riedel, R.
    Scheffler, M.
    Michels, S.
    Koleczko, S.
    Zadoyan, G.
    de Porre, P.
    Santiago-Walker, A.
    Sendler, A.
    Sueptitz, J.
    Yzbashi, L.
    Keser, E.
    Fischer, R. N.
    Abdulla, D. S. Y.
    Thomas, R. K.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 213 - 213
  • [47] FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib.
    Necchi, Andrea
    Siefker-Radtke, Arlene O.
    Zhong, Bob
    Mahadevia, Parthiv Jasvant
    Santiago-Walker, Ademi E.
    De Porre, Peter
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Debio 1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas
    Sait, Sameer Farouk
    Gilheeney, Stephen W.
    Bale, Tejus A.
    Haque, Sofia
    Dinkin, Marc J.
    Vitolano, Stephanie
    Rosenblum, Marc K.
    Ibanez, Katarzyna
    Prince, Daniel E.
    Spatz, Krisoula H.
    Dunkel, Ira J.
    Karajannis, Matthias A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 876 - 883
  • [49] FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
    Tao, Zhanchao
    Cui, Yue
    Xu, Xilong
    Han, Ting
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (40)
  • [50] Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
    Turcin Saridogan
    Argun Akcakanat
    Ming Zhao
    Kurt W. Evans
    Erkan Yuca
    Stephen Scott
    Bryce P. Kirby
    Xiaofeng Zheng
    Min Jin Ha
    Huiqin Chen
    Patrick K. S. Ng
    Timothy P. DiPeri
    Gordon B. Mills
    Jordi Rodon Ahnert
    Senthil Damodaran
    Funda Meric-Bernstam
    Scientific Reports, 13
12345